Lupin 2024

January 22, 2024

You can read some of the January 22nd print issue of Chain Drug Review here. In CDR’s digital editions, you can find special sections and additional pages not posted online. You will need to register, but subscription is free!

The Inflation Reduction Act’s impact on biosimilars

The Inflation Reduction Act’s impact on biosimilars

The Inflation Reduction Act (IRA), which was signed into law in August of 2022, announced several provisions on prescription drugs, with the aim of lowering the burden on people and reducing federal spending on drugs. Some of these provisions are targeted at high-cost biologic drugs and are in turn expected have a profound impact on

How iA is endeavoring to drive a ‘Movement’ in Rx

How iA is endeavoring to drive a ‘Movement’ in Rx

In the past three years, our industry has faced unprecedented challenges. Our pharmacists, technicians and support staff stepped up to the challenge and provided frontline care and services when they were needed the most. This dedication is admirable, yet the increasing demands for prescription fulfillment have brought to light the urgent need for change, for

AI and robotics are leading to ‘smart’ pharmacies

AI and robotics are leading to ‘smart’ pharmacies

Imagine C-3PO or R2-D2 delivering your medication to ensure you receive it on time. The pharmacy sector may not yet be Star Wars-ready, but today’s technology is making headway toward an AI, automated, robotic and more personalized future. The global pharmacy automation market totaled $5.6 billion in 2022 and is expected to grow by 8.4 % CAGR

McMillon heralds a new kind of retailing

McMillon heralds a new kind of retailing

When the history of Doug McMillon’s tenure as chief executive officer of Walmart is written, the central theme is sure to be the transformation of the company from one entrenched in brick-and-mortar retailing into a multidimensional enterprise. Walmart’s striking evolution over the decade since McMillan became CEO stems from his grasp of technology’s potential to

Health care outlook 2024: John O’Brien, president and CEO, NPC

Health care outlook 2024: John O’Brien, president and CEO, NPC

In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year.  2023 was a pivotal year for health policy, to say the least. The swift implementation of the IRA’s Medicare Drug Price Negotiation Program (DPNP) by the Centers for Medicare and Medicaid Services (CMS), the growing

Health care outlook 2024: Scott Melville, president and CEO, CHPA

Health care outlook 2024: Scott Melville, president and CEO, CHPA

In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The year 2023 marked another significant milestone for consumer health care with the continued growth of self-care driving the demand for safe and beneficial over-the-counter medicines, dietary supplements and consumer medical devices. Americans are prioritizing

Health care outlook 2024: Chip Davis, president and CEO HDA

Health care outlook 2024: Chip Davis, president and CEO HDA

In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. Health care policy issues will inevitably emerge as a topic of the national debate in the 2024 election season. Access and affordability remain part of the dialogue, and implementation of the Inflation Reduction Act —

Health care outlook 2024: Micah Cost, CEO, PQA

Health care outlook 2024: Micah Cost, CEO, PQA

In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. Former Defense Secretary Donald Rumsfeld once observed that “there are known knowns. There are things we know we know. We also know there are known unknowns. That is to say we know there are some

Health care outlook 2024: Ronald Piervincenzi, CEO, U.S. Pharmacopeia

Health care outlook 2024: Ronald Piervincenzi, CEO, U.S. Pharmacopeia

In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The past year was significant for the pharmaceutical industry, as we witnessed major milestones and celebrated advancements in innovation. We saw an official end to the COVID-19 pandemic public health emergency and unlocked the potential

PP_1170x120_10-25-21